Advertisements



Cassava expects topline results for Phase 2b study of PTI-125 in mid-year 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 26th, 2020

Cassava expects topline results from Phase 2b study of PTI-125 mid-year 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2020

Ocugen expects topline results for Phase 3 study of OCU300 by year-end

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 27th, 2020

Ocugen Provides Business Update and Full Year 2019 Financial Results

Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET.....»»

Category: earningsSource: benzingaMar 27th, 2020

miRagen Reports Fourth Quarter and Full Year 2019 Financial Results

Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020 Completed initial pla.....»»

Category: earningsSource: benzingaMar 11th, 2020

Cassava Sciences expects comprehensive study results from Phase 2b study in Q3

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 16th, 2020

Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020

Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson's disease, with data from this cohort expected in Q4 2020 Completed enrollment of low-dose cohort of Phase 1/2 clinical study of AXO-A.....»»

Category: smallbizSource: nytJun 10th, 2020

Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020

- Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Pha.....»»

Category: earningsSource: benzingaMay 18th, 2020

BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update

- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin for CIN in China in Q1 2020 - - On Track.....»»

Category: earningsSource: benzingaApr 30th, 2020

GENFIT Reports Full-Year 2019 Financial Results and Corporate Update

Topline interim results from Phase 3 clinical trial RESOLVE-IT expected by the end of May 2020 Cash position of €277MM as of December 31, 2019 (vs €207MM as of December 31, 2018) Significant milestones achieved i.....»»

Category: earningsSource: benzingaApr 8th, 2020

Xenon Pharmaceuticals expects results from Phase 2 study of XEN007 in 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 31st, 2020

Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

Seclidemstat Achieves Dose-Escalation Milestone in Phase 1/2 Ewing Sarcoma Clinical Trial Sixth Level Dosing Cohort Now Proceeding; On Track To Report Topline Data in 2020 HOUSTON, March 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.....»»

Category: earningsSource: benzingaMar 23rd, 2020

Corbus expects topline data from Phase 2b study in SLE in late 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 12th, 2020

Corbus expects topline data from Phase 2b study in CF in summer 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 12th, 2020

Corbus expects topline results from Phase 3 DETERMINE study in 2021

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 12th, 2020

Corbus expects topline results from Phase 3 RESOLVE-1 study in summer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 12th, 2020

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2020 Raised $65 million in gross proceeds from privat.....»»

Category: earningsSource: benzingaMar 12th, 2020

Albireo Pharma expects topline data from Phase 2 study of elobixibat by mid-2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 2nd, 2020

Albireo Pharma expects topline data from PEDFIC 1 Phase 3 study in mid-2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 2nd, 2020

Karyopharm expects topline data from Phase 3 portion of SEAL study in 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 13th, 2020

Molecular Templates expects interim results from Phase 2 DLBCL study in 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 8th, 2020